Anastrozole and Fulvestrant Compared to Anastrozole as Adjuvant Treatment of Postmenopausal Patients With Breast Cancer (@FAME)
A Randomised Phase II Study Comparing Anastrozole and Fulvestrant to Anastrozole for Adjuvant Treatment of Postmenopausal Patients With Early Breast Cancer and Disseminated Tumour Cells in Bone Marrow
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Feldkirch, Austria
- Research Site
-
Graz, Austria
- Research Site
-
Innsbruck, Austria
- Research Site
-
Klagenfurt, Austria
- Research Site
-
Leoben, Austria
- Research Site
-
Linz, Austria
- Research Site
-
Salzburg, Austria
- Research Site
-
St. Veit, Austria
- Research Site
-
Wien, Austria
- Research Site
-
Wiener Neustadt, Austria
- Research Site
-
-
-
-
-
Bayreuth, Germany
- Research Site
-
Essen, Germany
- Research Site
-
Hamburg-Eppendorf, Germany
- Research Site
-
Heidelberg, Germany
- Research Site
-
Munich, Germany
- Research Site
-
Rostock, Germany
- Research Site
-
Tubingen, Germany
- Research Site
-
-
-
-
-
Drammen, Norway
- Research Site
-
Fredrikstad, Norway
- Research Site
-
Kristiansand, Norway
- Research Site
-
Oslo, Norway
- Research Site
-
Porsgrunn, Norway
- Research Site
-
Stavanger, Norway
- Research Site
-
Tonsberg, Norway
- Research Site
-
Trondheim, Norway
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Postmenopausal women with hormone receptor-positive early breast cancer and a positive Disseminated Tumour Cell immunocytochemical result from bone marrow aspiration prior to randomisation
Exclusion Criteria:
- Inflammatory and/or metastatic breast cancer.
- Current or previous malignancy within previous 5 years (other than Breast cancer or adequately treated non-melanoma skin cancer or in-situ cervical cancer).
- History of bleeding diathesis.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: 2
Anastrozole + Fulvestrant
|
intramuscular injection
Other Names:
1 mg oral tablet
Other Names:
|
|
Active Comparator: 1
Anastrozole monotherapy
|
1 mg oral tablet
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patients Event-free at 12 Months (Where Event = Death (From Any Cause), Disseminated Tumour Cells (DTC) Positive at 12 Months or Clinical Disease Recurrence)
Time Frame: 12 month period following randomisation
|
Number of patients event-free
|
12 month period following randomisation
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Breast Cancer Established Brands Team Medical Science Director, MD, AstraZeneca
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Hormone Antagonists
- Aromatase Inhibitors
- Steroid Synthesis Inhibitors
- Estrogen Antagonists
- Estrogen Receptor Antagonists
- Fulvestrant
- Anastrozole
Other Study ID Numbers
Other Study ID Numbers
- D6990C00001
- ABCSG21
- Eudract No 2005-005715-22
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.